IP Library Granted Patent US 7,943,745
Granted Patent B2
US 7,943,745 · App. 12/295,991 · Granted May 17, 2011

Anti-CD98 antibody

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,943,745
App. No.
12/295,991
Granted
May 17, 2011
Kind
B2
Abstract

A human antibody or a functional fragment thereof having specific binding ability to CD98 which is derived from the cell membrane of cancer cells and is in the form of a complex with a protein having an amino acid transporter activity (for example, LAT1) is disclosed. This antibody binds to CD98 in the form of a dimer with LAT1 on the surface of cancer cells, specifically attacks cancer cells expressing CD98 via the immune system by ADCC or CDC, and further inhibits amino acid uptake of the cancer cells via LAT1, to suppress growth of the cancer cells. Accordingly, a preventive and therapeutic agent for cancer comprising this antibody or a fragment thereof, which acts on various cancers, is specific to cancer, and causes no side effect, is provided.

Claims (26)

1. A human monoclonal antibody or a functional fragment thereof that binds CD98 and that has any, pair of sequences of the following (b) to (g) as a heavy chain variable region and a light chain variable region:

(b) SEQ ID NOs: 41 and 47,

(c) SEQ ID NOs: 43 and 47,

(d) SEQ ID NOs: 43 and 77,

(e) SEQ ID NOs: 43 and 79,

(f) SEQ ID NOs: 43 and 81, and

(g) SEQ ID NOs: 43 and 83,

wherein said functional fragment is selected from the group consisting of Fab, Fab′, (Fab′)2, Fv, scFv, and sdFv of said antibody and a combination thereof.

2. The human monoclonal antibody or a functional fragment thereof according to claim 1 , wherein a subclass of the antibody heavy chain constant region is IgG.

3. A conjugate, comprising:

(i) the human monoclonal antibody or a functional fragment thereof according to any one of claim 1 or claim 2 ; and (ii) a heterogeneous domain containing a binding protein, an enzyme, a drug, a toxin, an immunomodulator, a detectable portion or a tag.

4. A cell expressing the human monoclonal antibody or a functional fragment thereof according to any one of claims 1 or 2 .

5. A pharmaceutical composition comprising the human monoclonal antibody or a functional fragment thereof according to any one of claims 1 or 2 as an active ingredient.

6. A therapeutic agent for colorectal cancer or colon cancer comprising the human monoclonal antibody or a functional fragment thereof according to any one of claims 1 or 2 as an active ingredient.

7. A method for producing an antibody that binds CD98, comprising:

introducing to a host cell an expression vector containing any pair of sequences of the following (b) to (g):

(b) SEQ ID NOs: 40 and 46,

(c) SEQ ID NOs: 42 and 46,

(d) SEQ ID NOs: 42 and 78,

(e) SEQ ID NOs: 42 and 80,

(f) SEQ ID NOs: 42 and 82, and

(g) SEQ ID NOs: 42 and 84,

or a degenerate nucleotide sequence thereof; then

culturing the host cell to produce a culture; and

obtaining the antibody from the culture.

8. The method according to claim 7 , wherein the host cell is selected from the group consisting of E. coli , yeast cells, insect cells, mammal cells, and plant cells.

Assignments (3)
MERGER Recorded Mar 23, 2009
From: KIRIN PHARMA CO., LTD.
To: KYOWA HAKKO KOGYO CO., LTD.
Reel/Frame 022435/0527 →
CHANGE OF NAME Recorded Mar 23, 2009
From: KYOWA HAKKO KOGYO CO., LTD.
To: KYOWA HAKKO KIRIN CO., LTD.
Reel/Frame 022435/0555 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 17, 2008
From: TAHARA, TOMOYUKI; KANAI, YOSHIKATSU; ENDOU, HITOSHI; KATAOKA, SHIRO; HASEGAWA, KAZUMASA; YOSHINO, TETSUYA
To: KIRIN PHARMA KABUSHIKI KAISHA
Reel/Frame 021699/0146 →